Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca's Lynparza Supplemental New Drug Application Granted Priority Review by FDA

11/30/2021 | 02:34am EST

By Anthony O. Goriainoff

AstraZeneca PLC said Tuesday that its Lynparza drug's supplemental new drug application has been accepted and granted Priority Review by the U.S. Food and Drug Administration.

Lynparza is used for the treatment of patients with early breast cancer who have already been treated with chemotherapy either before or after surgery, the London-listed company said.

The Anglo-Swedish pharmaceutical company said the application was based on results from the OlympiA phase 3 trial which showed Lynparza demonstrated a statistically significant improvement in invasive disease-free survival.

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

(END) Dow Jones Newswires

11-30-21 0234ET

All news about ASTRAZENECA PLC
07:50aSAP to buy U.S. fintech Taulia; eyes metaverse opportunities
RE
01/25Valneva Includes Booster Shots in Late-Stage Study of COVID-19 Jab
MT
01/25Valneva Starts Extended Trial to Study Booster Shot of COVID-19 Vaccine; Shares Up 9%
MT
01/25Orange Corners South Africa and AstraZeneca South Africa join forces in a new partnersh..
AQ
01/25Germany to receive 3.8 mln doses of Novavax's new COVID vaccine in Q1
RE
01/25Orange Corners South Africa and AstraZeneca South Africa join forces in a new partnersh..
AQ
01/25Egetis appoints Karl Hård as Head of Investor Relations and Communication
AQ
01/24PCI Biotech Loses 10% As It Discontinues Cancer Trial To Focus On Immunotherapies
MT
01/24AstraZeneca's Rare Progressive Disease Drug Granted US FDA Orphan Drug Tag
MT
01/24Sinovac regimen gets strong boost from Pfizer, AstraZeneca or J&J COVID shots - study
RE
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 36 228 M - -
Net income 2021 2 276 M - -
Net Debt 2021 24 734 M - -
P/E ratio 2021 57,4x
Yield 2021 2,46%
Capitalization 177 B 178 B -
EV / Sales 2021 5,57x
EV / Sales 2022 4,57x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 114,21 $
Average target price 139,09 $
Spread / Average Target 21,8%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC-2.27%177 586
JOHNSON & JOHNSON-1.57%443 277
ROCHE HOLDING AG-7.91%306 143
PFIZER, INC.-10.23%297 538
ABBVIE INC.-0.86%237 303
ELI LILLY AND COMPANY-13.89%215 642